Last Price$92.81.8%
Market Cap$75.3B
LTM Research & Development Expenses (R&D)
$0.0
YoY Growth
-100.0%
3Y CAGR
-100.0%
5Y CAGR
-100.0%
Stock quality & Intrinsic value
7/10
10.2% overvalued
Colgate-Palmolive Company Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $259.0M | $267.0M | $277.0M | $274.0M | $289.0M | $285.0M | $277.0M | $281.0M | $290.0M | $307.0M | $320.0M | $343.0M | $0.0 |
Overvalued or undervalued?
Check the intrinsic value for CL
and see if it's the right time to invest.
Colgate-Palmolive Company (CL) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Colgate-Palmolive CompanyCL
$0.0
(100.0%)
(100.0%)
(100.0%)
Median Peer Set
$102.8M
(2.6%)
0.0%
0.0%
Unilever PLCUL
$1,026.6M
(44.5%)
(19.2%)
(13.8%)
The Estée Lauder Companies Inc.EL
$360.0M
4.7%
N/A
12.3%
Kenvue Inc.KVUE
$205.0M
(48.6%)
26.2%
N/A
The Clorox CompanyCLX
$127.0M
(5.2%)
(4.1%)
(1.4%)
Coty Inc.COTY
$126.8M
20.5%
9.5%
N/A
Hims & Hers Health, Inc.HIMS
$78.8M
63.4%
88.3%
N/A
Church & Dwight Co., Inc.CHD
$63.1M
(48.4%)
(15.7%)
(7.6%)
Kimberly-Clark CorporationKMB
$0.0
(100.0%)
(100.0%)
(100.0%)
e.l.f. Beauty, Inc.ELF
$0.0
N/A
N/A
N/A
The Procter & Gamble CompanyPG
$0.0
N/A
N/A
N/A
CL key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 11,396.9 7.7% | 12,237.7 7.4% | 13,789.7 12.7% | 15,329.9 11.2% | 15,327.0 (0.0%) | 15,564.0 1.5% | 16,734.0 7.5% | 17,085.0 2.1% | 17,420.0 2.0% | 17,277.0 (0.8%) | 16,034.0 (7.2%) | 15,195.0 (5.2%) | 15,454.0 1.7% | 15,544.0 0.6% | 15,693.0 1.0% | 16,471.0 5.0% | 17,421.0 5.8% | 17,967.0 3.1% | 19,457.0 8.3% | 20,101.0 3.3% |
| Cost of Goods Sold (COGS) | 5,191.9 | 5,536.1 | 6,042.3 | 6,703.5 | 6,319.0 | 6,360.0 | 7,144.0 | 7,153.0 | 7,219.0 | 7,168.0 | 6,635.0 | 6,072.0 | 6,174.0 | 6,313.0 | 6,368.0 | 6,454.0 | 7,046.0 | 7,719.0 | 8,131.0 | 7,940.0 |
% margin | 6,205.0 54.4% | 6,701.6 54.8% | 7,747.4 56.2% | 8,626.4 56.3% | 9,008.0 58.8% | 9,204.0 59.1% | 9,590.0 57.3% | 9,932.0 58.1% | 10,201.0 58.6% | 10,109.0 58.5% | 9,399.0 58.6% | 9,123.0 60.0% | 9,280.0 60.0% | 9,231.0 59.4% | 9,325.0 59.4% | 10,017.0 60.8% | 10,375.0 59.6% | 10,248.0 57.0% | 11,326.0 58.2% | 12,161.0 60.5% |
| Operating Expenses | 3,990.0 | 4,388.0 | 5,038.7 | 5,605.7 | 5,393.0 | 5,414.0 | 5,749.0 | 6,043.0 | 6,645.0 | 6,552.0 | 5,526.0 | 5,271.0 | 5,691.0 | 5,537.0 | 5,771.0 | 6,132.0 | 6,472.0 | 6,634.0 | 7,343.0 | 7,893.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 259.0 | 267.0 | 277.0 | 274.0 | 289.0 | 285.0 | 277.0 | 281.0 | 290.0 | 307.0 | 320.0 | 343.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 3,920.8 | 4,355.2 | 4,973.0 | 5,422.3 | 5,282.0 | 5,414.0 | 5,758.0 | 5,930.0 | 6,223.0 | 5,982.0 | 5,464.0 | 5,249.0 | 5,497.0 | 5,389.0 | 5,575.0 | 6,019.0 | 6,407.0 | 6,565.0 | 7,151.0 | 7,729.0 |
% margin | 2,215.0 19.4% | 2,160.5 17.7% | 2,653.1 19.2% | 3,020.7 19.7% | 3,615.0 23.6% | 3,790.0 24.4% | 3,841.0 23.0% | 3,889.0 22.8% | 3,556.0 20.4% | 3,557.0 20.6% | 2,789.0 17.4% | 3,837.0 25.3% | 3,589.0 23.2% | 3,694.0 23.8% | 3,554.0 22.6% | 3,885.0 23.6% | 4,474.0 25.7% | 4,335.0 24.1% | 3,984.0 20.5% | 4,268.0 21.2% |
| Interest Income | 0.0 | 0.0 | 0.0 | 10.0 | 11.0 | 6.0 | 7.0 | 65.0 | 125.0 | 106.0 | 107.0 | 50.0 | 51.0 | 50.0 | 47.0 | 19.0 | 17.0 | 14.0 | 55.0 | 67.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 105.6 | 77.0 | 59.0 | 59.0 | 80.0 | 116.0 | 130.0 | 133.0 | 149.0 | 153.0 | 193.0 | 192.0 | 183.0 | 192.0 | 167.0 | 287.0 | 292.0 |
| Pre-tax Income | 2,079.0 | 2,001.8 | 2,496.5 | 2,925.1 | 3,538.0 | 3,430.0 | 3,789.0 | 3,874.0 | 3,565.0 | 3,533.0 | 2,763.0 | 3,738.0 | 3,487.0 | 3,464.0 | 3,301.0 | 3,647.0 | 3,087.0 | 2,660.0 | 3,392.0 | 3,956.0 |
% effective tax rate | 727.6 35.0% | 648.4 32.4% | 759.1 30.4% | 967.9 33.1% | 1,141.0 32.2% | 1,117.0 32.6% | 1,235.0 32.6% | 1,243.0 32.1% | 1,155.0 32.4% | 1,194.0 33.8% | 1,215.0 44.0% | 1,152.0 30.8% | 1,313.0 37.7% | 906.0 26.2% | 774.0 23.4% | 787.0 21.6% | 749.0 24.3% | 693.0 26.1% | 937.0 27.6% | 907.0 22.9% |
% margin | 1,351.4 11.9% | 1,353.4 11.1% | 1,737.4 12.6% | 1,957.2 12.8% | 2,291.0 14.9% | 2,203.0 14.2% | 2,431.0 14.5% | 2,472.0 14.5% | 2,241.0 12.9% | 2,180.0 12.6% | 1,384.0 8.6% | 2,441.0 16.1% | 2,024.0 13.1% | 2,400.0 15.4% | 2,367.0 15.1% | 2,695.0 16.4% | 2,166.0 12.4% | 1,785.0 9.9% | 2,300.0 11.8% | 2,889.0 14.4% |
| EPS | 1.27 | 1.29 | 1.68 | 1.91 | 2.27 | 2.23 | 2.49 | 2.60 | 2.41 | 2.38 | 1.53 | 2.74 | 2.30 | 2.76 | 2.76 | 3.15 | 2.56 | 2.13 | 2.78 | 3.53 |
| Diluted EPS | 1.22 | 1.23 | 1.60 | 1.83 | 2.19 | 2.15 | 2.47 | 2.58 | 2.38 | 2.36 | 1.52 | 2.72 | 2.28 | 2.75 | 2.75 | 3.14 | 2.55 | 2.13 | 2.77 | 3.51 |
% margin | 2,606.1 22.9% | 2,554.6 20.9% | 3,064.1 22.2% | 3,458.6 22.6% | 3,977.0 25.9% | 3,871.0 24.9% | 4,268.0 25.5% | 4,379.0 25.6% | 4,120.0 23.7% | 4,105.0 23.8% | 3,345.0 20.9% | 4,330.0 28.5% | 4,115.0 26.6% | 4,168.0 26.8% | 4,163.0 26.5% | 4,327.0 26.3% | 4,369.0 25.1% | 4,127.0 23.0% | 4,246.0 21.8% | 4,268.0 21.2% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Colgate-Palmolive Company's Research & Development Expenses (R&D)?
As of today, Colgate-Palmolive Company's last 12-month Research & Development Expenses (R&D) is $0.0, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Colgate-Palmolive Company's Research & Development Expenses (R&D) growth rate?
Over the last year, Colgate-Palmolive Company's Research & Development Expenses (R&D) growth was (100.0%). The average annual Research & Development Expenses (R&D) growth rates for Colgate-Palmolive Company have been (100.0%) over the past three years, (100.0%) over the past five years.
3) Is Colgate-Palmolive Company's Research & Development Expenses (R&D) growth rate Good?
Over the last year, Colgate-Palmolive Company's Research & Development Expenses (R&D) growth was (100.0%), which is lower than industry growth of (0.9%). It indicates that Colgate-Palmolive Company's Research & Development Expenses (R&D) growth is Good.